Literature DB >> 15774252

Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders.

Dimitrios Hatzichristou1, Kyriakos Moysidis, Apostolos Apostolidis, Athanasios Bekos, Vasilios Tzortzis, Konstantinos Hatzimouratidis, Evangelos Ioannidis.   

Abstract

OBJECTIVE: The objective of this study was to identify factors that affect efficacy response rate to sildenafil in the clinical practice. MATERIAL AND
METHOD: The study comprised 100 consecutive sildenafil non-responders. Mean patient age was 59+/-14.4 years and mean duration of ED 5.5+/-6.4 years. All patients underwent detailed medical and sexual history and completed the IIEF and a questionnaire regarding the previous use of sildenafil. When inadequate instructions were reported, information on the appropriate use of sildenafil was given and patients were asked to use at least 4 tablets at home. Pharmacologic efficacy was re-evaluated in a scheduled follow-up visit.
RESULTS: Mean Erectile Function Domain (ED) of the IIEF score was 14+/-9.9. In 56 patients inappropriate use of sildenafil was recognized; 45 had never used the highest recommended dose (100 mg), 32 had taken the pill with a full stomach right after a meal, 22 had taken the pill just before the initiation of sexual activity and 12 were not aware that sexual stimulation was mandatory to achieve an erection. Furthermore, 8 patients had tried the 100mg dose, despite the presence of factors associated with sildenafil clearance reduction (renal insufficiency, cimetidine treatment). Only 34 patients reported that their physician had scheduled a follow-up visit. Following adequate dose titration and time adjustment, 31 patients responded to sildenafil; 10 patients used the 50 mg dose and 21 the 100 mg. Second and third-line treatment options were offered to the rest of the patients.
CONCLUSIONS: ED patients may receive inadequate instructions with their prescriptions. Response rate to sildenafil may be maximized after receiving appropriate dose titration and instructions on administration. ED should be treated in the same way as other chronic conditions; follow-up is necessary to evaluate the appropriate application and pharmacologic efficacy of the proposed treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774252     DOI: 10.1016/j.eururo.2004.12.005

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

Review 1.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

Review 2.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.

Authors:  Ying-Lu Guo; Vijay P Viswanathan; Han-Sun Chiang; Hyung Ki Choi; Andrew Wai Chun Yip; Wei Shen; Vladimir Kopernicky
Journal:  Asian J Androl       Date:  2009-04-20       Impact factor: 3.285

4.  Treatment Strategy for Non-Responders to PDE5 Inhibitors.

Authors:  Nam Cheol Park; Tae Nam Kim; Hyun Jun Park
Journal:  World J Mens Health       Date:  2013-04-23       Impact factor: 5.400

5.  Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment.

Authors:  Valter Javaroni; Mario Fritsch Neves
Journal:  Int J Hypertens       Date:  2012-05-09       Impact factor: 2.420

6.  Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.

Authors:  Ioannis Mykoniatis; Nikolaos Pyrgidis; Ioannis Sokolakis; Andreas Ouranidis; Petros Sountoulides; Anna-Bettina Haidich; Koenraad van Renterghem; Georgios Hatzichristodoulou; Dimitrios Hatzichristou
Journal:  JAMA Netw Open       Date:  2021-02-01

Review 7.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

Review 8.  Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Konstantinos Hatzimouratidis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

Review 9.  Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.

Authors:  Ji Kan Ryu; Kang Su Cho; Su Jin Kim; Kyung Jin Oh; Sung Chul Kam; Kyung Keun Seo; Hong Seok Shin; Soo Woong Kim
Journal:  World J Mens Health       Date:  2013-08-31       Impact factor: 5.400

10.  Association of psychological factors, patients' knowledge, and management among patients with erectile dysfunction.

Authors:  Hasniza Zaman Huri; Nurul Diyana Mat Sanusi; Azad Hassan Abdul Razack; Raymond Mark
Journal:  Patient Prefer Adherence       Date:  2016-05-13       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.